FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283442> ?p ?o ?g. }

• W4379283442 endingPage "e14555" @default.
• W4379283442 startingPage "e14555" @default.
• W4379283442 abstract "e14555 Background: 9-ING-41 (elraglusib) is a novel inhibitor of GSK-3β that has shown early signs of clinical benefit in a phase 1/2 clinical trial (ACT1801; NCT03678883). Early data support a multi-modal mechanism of action for elraglusib that targets both the tumor and immune system. Thus, the discovery and validation of biomarkers of drug sensitivity to elraglusib is a high priority. Here, we take inspiration from the literature on checkpoint inhibitor therapy and explore the potential of cytokines to predict elraglusib clinical response. Methods: Peripheral plasma samples from 59 patients enrolled in the 1801 phase 1/2 trial of elraglusib were assayed for 40 circulating cytokine levels. Patients advanced solid tumors refractory to standard treatments and received either elraglusib (1.0-15.0 mg/kg) as a single agent or in combination with other chemotherapies. Samples were taken from time points prior to elraglusib administration (pre-dose), after cycle 1, or after cycle 2. Each cytokine time point combination was used to stratify patients into high and low categories using an optimal cut-point determined using maximally selected rank statistics. Kaplan Meier and Cox Proportional Hazards analysis was used to determine the efficacy of each cytokine as a biomarker. The change in cytokine values between pre-dose and cycle 1 or pre-dose and cycle 2 was evaluated in a similar manner. Results: A total of 142 samples spanning eight different tumor histologies were collected and analyzed. A total of 240 cytokine-timepoint combinations were evaluated, and 53 significantly stratified patients by overall survival (p-value < 0.05). Of those, 35 showed that higher levels of the given cytokine correlated with a survival benefit and 18 a survival decrease. Notable among the cytokines demonstrating survival benefits were Granzyme B at Cycle 1 Day 4 (HR: 9.54, p-value:0.015) and TGF β at Cycle 1 Day 4 (HR: 8.48, p-value:0.0063). Strong hazard ratios were also observed for cytokines that correlated with survival decreases including TRAIL-R2 at Cycle 1 Day 2 (HR: 9.56e-02, p-value:0.0001), and IL-10 at Cycle 1 Day 4 (HR: 8.77e-02, p-value:0.007). Delta between timepoints was also able to stratifying patients by overall survival. Conclusions: Plasma cytokine profiling is a promising approach for discovery and validation of biomarkers prognostic for elraglusib clinical benefit. Numerous cytokines measured pre-dose stratified patients into significant survival groups suggesting a potential strategy for patient enrichment in clinical trials of elraglusib. These initial findings are being expanded by 1) increasing the cohort to accommodate histology specific investigations; 2) examining which cytokines are elraglusib response-specific versus drug-agnostic; and 3) combining cytokines in multivariate and machine learning models for optimal predictive capacity. Clinical trial information: NCT03678883 ." @default.
• W4379283442 created "2023-06-05" @default.
• W4379283442 creator A5003384453 @default.
• W4379283442 creator A5004814161 @default.
• W4379283442 creator A5009111092 @default.
• W4379283442 creator A5029992402 @default.
• W4379283442 creator A5045906008 @default.
• W4379283442 creator A5061285204 @default.
• W4379283442 creator A5065530824 @default.
• W4379283442 creator A5069923958 @default.
• W4379283442 creator A5075201353 @default.
• W4379283442 creator A5083373965 @default.
• W4379283442 date "2023-06-01" @default.
• W4379283442 modified "2023-09-25" @default.
• W4379283442 title "Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer." @default.
• W4379283442 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e14555" @default.
• W4379283442 hasPublicationYear "2023" @default.
• W4379283442 type Work @default.
• W4379283442 citedByCount "0" @default.
• W4379283442 crossrefType "journal-article" @default.
• W4379283442 hasAuthorship W4379283442A5003384453 @default.
• W4379283442 hasAuthorship W4379283442A5004814161 @default.
• W4379283442 hasAuthorship W4379283442A5009111092 @default.
• W4379283442 hasAuthorship W4379283442A5029992402 @default.
• W4379283442 hasAuthorship W4379283442A5045906008 @default.
• W4379283442 hasAuthorship W4379283442A5061285204 @default.
• W4379283442 hasAuthorship W4379283442A5065530824 @default.
• W4379283442 hasAuthorship W4379283442A5069923958 @default.
• W4379283442 hasAuthorship W4379283442A5075201353 @default.
• W4379283442 hasAuthorship W4379283442A5083373965 @default.
• W4379283442 hasConcept C121332964 @default.
• W4379283442 hasConcept C126322002 @default.
• W4379283442 hasConcept C142424586 @default.
• W4379283442 hasConcept C143998085 @default.
• W4379283442 hasConcept C185592680 @default.
• W4379283442 hasConcept C203092338 @default.
• W4379283442 hasConcept C2778690821 @default.
• W4379283442 hasConcept C2781197716 @default.
• W4379283442 hasConcept C50382708 @default.
• W4379283442 hasConcept C535046627 @default.
• W4379283442 hasConcept C55493867 @default.
• W4379283442 hasConcept C71924100 @default.
• W4379283442 hasConcept C87355193 @default.
• W4379283442 hasConceptScore W4379283442C121332964 @default.
• W4379283442 hasConceptScore W4379283442C126322002 @default.
• W4379283442 hasConceptScore W4379283442C142424586 @default.
• W4379283442 hasConceptScore W4379283442C143998085 @default.
• W4379283442 hasConceptScore W4379283442C185592680 @default.
• W4379283442 hasConceptScore W4379283442C203092338 @default.
• W4379283442 hasConceptScore W4379283442C2778690821 @default.
• W4379283442 hasConceptScore W4379283442C2781197716 @default.
• W4379283442 hasConceptScore W4379283442C50382708 @default.
• W4379283442 hasConceptScore W4379283442C535046627 @default.
• W4379283442 hasConceptScore W4379283442C55493867 @default.
• W4379283442 hasConceptScore W4379283442C71924100 @default.
• W4379283442 hasConceptScore W4379283442C87355193 @default.
• W4379283442 hasIssue "16_suppl" @default.
• W4379283442 hasLocation W43792834421 @default.
• W4379283442 hasOpenAccess W4379283442 @default.
• W4379283442 hasPrimaryLocation W43792834421 @default.
• W4379283442 hasRelatedWork W1608269846 @default.
• W4379283442 hasRelatedWork W2015659076 @default.
• W4379283442 hasRelatedWork W2046855179 @default.
• W4379283442 hasRelatedWork W2938415695 @default.
• W4379283442 hasRelatedWork W3089163820 @default.
• W4379283442 hasRelatedWork W3192124157 @default.
• W4379283442 hasRelatedWork W4210755456 @default.
• W4379283442 hasRelatedWork W4225398559 @default.
• W4379283442 hasRelatedWork W4282918911 @default.
• W4379283442 hasRelatedWork W4313588118 @default.
• W4379283442 hasVolume "41" @default.
• W4379283442 isParatext "false" @default.
• W4379283442 isRetracted "false" @default.
• W4379283442 workType "article" @default.